Genzyme Corp. and Bayer Schering Pharma AG began the first of two planned Phase III trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS). The CARE-MS I trial (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis), a randomized study, will compare alemtuzumab to Rebif (interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (MS). Alemtuzumab will be given in two annual cycles; Rebif will be administered three t...